#aduhelm

The rocky road that the Alzheimer’s drug Aduhelm experienced on its way to FDA approval was considered a hard-fought victory by proponents, but skeptics and critics may feel redeemed as Biogen announced Jan. 31 that it will discontinue production and research of the controversial drug. Biogen’s announcement to abandon Aduhelm comes just two and a half years after the drug received accelerated…

From well to sick…

Wellness x Illness crossroad; Credit:gustavofrazao Image purchased from iStock An Op-Ed article by Patricia Bencivenga and Judy Butler, published on 14 October 2022 in the Pittsbert Post Gazette, Drug company tricks: Gaslighting the worried well into becoming the worried sick, highlights the power of the rich parhmaceutical companues, and their hold on research progress, researchers and dementia…